TP53 and myelodysplastic syndrome: Cryptic SVs were only identified in patients with ≤3 mutations detected by NGS, with the highest yield in patients with fewer mutations [1–2 per sample, ~48%; MDS with TP53 (16, 73%) and SF3B1 mutations (7, 25%)] (Supplementary Fig. S4).